Zimmer Biomet Competitors

Zimmer Biomet (NYSE:ZBH) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

87.2% of Zimmer Biomet shares are held by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are held by institutional investors. 0.4% of Zimmer Biomet shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Zimmer Biomet and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Intuitive Surgical has lower revenue, but higher earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Zimmer Biomet has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Zimmer Biomet and Intuitive Surgical, as reported by MarketBeat.

Zimmer Biomet currently has a consensus target price of $167.8636, suggesting a potential downside of 3.41%. Intuitive Surgical has a consensus target price of $750.9444, suggesting a potential downside of 7.85%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, research analysts clearly believe Zimmer Biomet is more favorable than Intuitive Surgical.

Profitability

This table compares Zimmer Biomet and Intuitive Surgical's net margins, return on equity and return on assets.

Summary

Zimmer Biomet beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.

Zimmer Biomet (NYSE:ZBH) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Zimmer Biomet and Edwards Lifesciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent recommendations for Zimmer Biomet and Edwards Lifesciences, as provided by MarketBeat.com.

Zimmer Biomet presently has a consensus price target of $167.8636, suggesting a potential downside of 3.41%. Edwards Lifesciences has a consensus price target of $91.1569, suggesting a potential upside of 0.43%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Zimmer Biomet.

Valuation & Earnings

This table compares Zimmer Biomet and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Zimmer Biomet has higher revenue and earnings than Edwards Lifesciences. Zimmer Biomet is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

87.2% of Zimmer Biomet shares are held by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are held by institutional investors. 0.4% of Zimmer Biomet shares are held by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Zimmer Biomet has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Summary

Zimmer Biomet beats Edwards Lifesciences on 9 of the 15 factors compared between the two stocks.

Align Technology (NASDAQ:ALGN) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Align Technology and Zimmer Biomet's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Align Technology and Zimmer Biomet, as provided by MarketBeat.

Align Technology presently has a consensus price target of $502.1667, suggesting a potential downside of 14.97%. Zimmer Biomet has a consensus price target of $167.8636, suggesting a potential downside of 3.41%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than Align Technology.

Valuation and Earnings

This table compares Align Technology and Zimmer Biomet's top-line revenue, earnings per share (EPS) and valuation.

Zimmer Biomet has higher revenue and earnings than Align Technology. Zimmer Biomet is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

85.8% of Align Technology shares are held by institutional investors. Comparatively, 87.2% of Zimmer Biomet shares are held by institutional investors. 1.2% of Align Technology shares are held by insiders. Comparatively, 0.4% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Align Technology has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500.

Summary

Zimmer Biomet beats Align Technology on 9 of the 15 factors compared between the two stocks.

STERIS (NYSE:STE) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for STERIS and Zimmer Biomet, as provided by MarketBeat.

STERIS presently has a consensus price target of $214.25, suggesting a potential upside of 1.74%. Zimmer Biomet has a consensus price target of $167.8636, suggesting a potential downside of 3.41%. Given STERIS's higher probable upside, equities research analysts clearly believe STERIS is more favorable than Zimmer Biomet.

Dividends

STERIS pays an annual dividend of $1.60 per share and has a dividend yield of 0.8%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.6%. STERIS pays out 28.4% of its earnings in the form of a dividend. Zimmer Biomet pays out 12.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has increased its dividend for 15 consecutive years and Zimmer Biomet has increased its dividend for 1 consecutive years. STERIS is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

90.0% of STERIS shares are held by institutional investors. Comparatively, 87.2% of Zimmer Biomet shares are held by institutional investors. 1.2% of STERIS shares are held by insiders. Comparatively, 0.4% of Zimmer Biomet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

STERIS has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Profitability

This table compares STERIS and Zimmer Biomet's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares STERIS and Zimmer Biomet's top-line revenue, earnings per share (EPS) and valuation.

Zimmer Biomet has higher revenue and earnings than STERIS. Zimmer Biomet is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Zimmer Biomet (NYSE:ZBH) and Smith & Nephew (NYSE:SNN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Zimmer Biomet and Smith & Nephew, as provided by MarketBeat.com.

Zimmer Biomet presently has a consensus target price of $167.8636, suggesting a potential downside of 3.41%. Smith & Nephew has a consensus target price of $47.1667, suggesting a potential upside of 19.26%. Given Smith & Nephew's higher probable upside, analysts clearly believe Smith & Nephew is more favorable than Zimmer Biomet.

Dividends

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.6%. Smith & Nephew pays an annual dividend of $0.90 per share and has a dividend yield of 2.3%. Zimmer Biomet pays out 12.2% of its earnings in the form of a dividend. Smith & Nephew pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zimmer Biomet has increased its dividend for 1 consecutive years and Smith & Nephew has increased its dividend for 1 consecutive years.

Institutional & Insider Ownership

87.2% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 8.9% of Smith & Nephew shares are owned by institutional investors. 0.4% of Zimmer Biomet shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Zimmer Biomet has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Zimmer Biomet and Smith & Nephew's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Zimmer Biomet and Smith & Nephew's gross revenue, earnings per share (EPS) and valuation.

Zimmer Biomet has higher revenue and earnings than Smith & Nephew. Smith & Nephew is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Summary

Zimmer Biomet beats Smith & Nephew on 14 of the 17 factors compared between the two stocks.

Zimmer Biomet (NYSE:ZBH) and MSA Safety (NYSE:MSA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Zimmer Biomet and MSA Safety, as provided by MarketBeat.com.

Zimmer Biomet presently has a consensus target price of $167.8636, suggesting a potential downside of 3.41%. MSA Safety has a consensus target price of $151.50, suggesting a potential downside of 1.39%. Given MSA Safety's higher probable upside, analysts clearly believe MSA Safety is more favorable than Zimmer Biomet.

Dividends

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.6%. MSA Safety pays an annual dividend of $1.72 per share and has a dividend yield of 1.1%. Zimmer Biomet pays out 12.2% of its earnings in the form of a dividend. MSA Safety pays out 35.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zimmer Biomet has increased its dividend for 1 consecutive years and MSA Safety has increased its dividend for 11 consecutive years. MSA Safety is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Institutional & Insider Ownership

87.2% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 77.2% of MSA Safety shares are owned by institutional investors. 0.4% of Zimmer Biomet shares are owned by insiders. Comparatively, 7.0% of MSA Safety shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Zimmer Biomet has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, MSA Safety has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.

Profitability

This table compares Zimmer Biomet and MSA Safety's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Zimmer Biomet and MSA Safety's gross revenue, earnings per share (EPS) and valuation.

Zimmer Biomet has higher revenue and earnings than MSA Safety. Zimmer Biomet is trading at a lower price-to-earnings ratio than MSA Safety, indicating that it is currently the more affordable of the two stocks.

Summary

Zimmer Biomet beats MSA Safety on 11 of the 18 factors compared between the two stocks.